Xiang Yi

Company: Amgen Inc.

Job title: Principal scientist

Seminars:

Mechanistic Study of Reversible & Irreversible Covalent Inhibitors 12:30 pm

The emergence of reversible covalency addresses off-target safety concerns, countering challenges posed by irreversible covalent inhibitors. Yet, characterization of this novel mechanism is hindered by limited assays and tools Establishing enzyme kinetic assays, incorporating slow binding Ki Kinact measurement and jump dilution to enable the determination and differentiation of reversible from irreversible covalency mechanismRead more

day: Conference Day One